Antiphospholipid antibodies and atherosclerosis: Insights from systemic lupus erythematosus and primary antiphospholipid syndrome

Clinical Reviews in Allergy and Immunology

Volumn 37, Issue 1, 2009, Pages 29-35

  Ames, Paul R J ^a   Margarita, Annamaria ^b   Alves, Jose Delgado ^c  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b CARDARELLI HOSPITAL   (Italy)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Antiphospholipid antibodies; Atherosclerosis; Primary antiphospholipid syndrome; Systemic lupus erythematosus

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BLOOD; CAROTID ARTERY; CASE CONTROL STUDY; ECHOGRAPHY; FEMALE; HUMAN; IMMUNOLOGY; INCIDENCE; INTIMA; MALE; MIDDLE AGED; PATHOLOGY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TUNICA MEDIA;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CAROTID ARTERIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; TUNICA INTIMA; TUNICA MEDIA;

EID: 70350434537     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-008-8099-5     Document Type: Article

References (68)

1. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
2. Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69-75 (Pubitemid 46670686)
3. Cervera R, Khamashta MA, Font J et al (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine 78:167-175 (Pubitemid 29231143)
4. Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019-1027 (Pubitemid 34303815)
5. Touboul PJ, Labreuche J, Vicaut E et al (2005) Carotid Intima-Media Thickness, Plaques, and Framingham Risk Score as Independent Determinants of Stroke Risk. Stroke 36:1741-1745 (Pubitemid 41098773)
6. Manzi S, Selzer F, Sutton-Tyrrell K et al (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51-60 (Pubitemid 29042570)
7. Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399-2406
8. Svenungsson E, Jensen-Urstad K, Heimbürger M et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887
9. Jiménez S, García-Criado MA, Tàssies D et al (2005) Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 44:756-761 (Pubitemid 41487204)
10. Sato H, Miida T, Wada Y et al (2007) Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin Chim Acta 385:35-42 (Pubitemid 47376930)
11. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM (2003) Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 42:645-651 (Pubitemid 37220873)
12. Falaschi F, Ravelli A, Martignoni A et al (2000) Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 43:1405-1409 (Pubitemid 30416328)
13. Rossi M, Mosca M, Tani C, Franzoni F, Santoro G, Bombardieri S (2008) Integrated backscatter analysis of carotid intima-media complex in patients with systemic lupus erythematosus. Clin Rheumatol (in press)
14. de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M (2006) Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15:675-682 (Pubitemid 44682830)
15. Wolak T, Todosoui E, Szendro G et al (2004) Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J Rheumatol 31:909-914 (Pubitemid 38585813)
16. Bowser CS, Kumar S, Salciccioli L et al (2008) Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus. Pediatr Cardiol 29:545-551
17. Roman MJ, Crow MK, Lockshin MD et al (2007) Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 56:3412-3419 (Pubitemid 47585436)
18. Thompson T, Sutton-Tyrrell K, Wildman RP et al (2008) Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 58:835-842 (Pubitemid 351364882)
19. Bilora F, Boccioletti V, Girolami B et al (2002) Are antiphospholipid antibodies an independent risk factor for atherosclerosis? Clin Appl Thromb Hemost 8:103 -113
20. Medina G, Casaos D, Jara LJ et al (2003) Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 62:607-610
21. Der H, Kerekes G, Veres K et al (2007) Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 16:497-503 (Pubitemid 47242523)
22. Margarita A, Batuca J, Scenna J et al (2007) Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci 1108:475-480 (Pubitemid 47528761)
23. Ames PRJ, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V (2002) Anticardiolipin antibody titre and plasma homocysteine levels independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11:208-214 (Pubitemid 34506724)
24. Belizna CC, Richard V, Primard E et al (2008) Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. Semin Arthritis Rheum 37:373 -380
25. Alarcon-Segovia D, Cardiel MH, Reyes E (1989) Antiphospholipid arterial vasculopathy. J Rheumatol 16:762-767 (Pubitemid 19182960)
26. Lie JT (1989) Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both? J Rheumatol 16:713-715
27. Taylor LM Jr, Chitwood RW, Dalman RL, Sexton G, Goodnight SH, Porter JM (1994) Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study. Ann Surg 220:544-551
28. Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK (1995) Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 238:437-443
29. Friehs I, Eber B, Friehs G, Langsteger W, Koch G (1992) IgG-anticardiolipin-antibodies are markers for cerebral and peripheral artery disease. Vasa 21:158-162
30. Fligelstone LJ, Cachia PG, Ralis H et al (1995) Lupus anticoagulant in patients with peripheral vascular disease: a prospective study. Eur J Vasc Endovasc Surg 9:277-283
31. Vig S, Chitolie A, Bevan D, Dormandy J, Thompson MM, Halliday A (2006) The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease. Br J Surg 93:577-581
32. Durga J, Verhoef P, Bots ML, Schouten E (2004) Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis 176:1-19 (Pubitemid 39078639)
33. Voutilainen S, Morrow JD, Roberts LJ 2nd et al (1999) Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol 19:1263 -1266
34. Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bächler JP (2007) Relationship between oxidative stress and essential hypertension. Hypertens Res 30:1159-1167 (Pubitemid 351176413)
35. Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre R (2006) Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 41:1031-1040 (Pubitemid 44348872)
36. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152- 154
37. Nourooz-Zadeh J, Cooper MB, Ziegler D, Betteridge DJ (2005) Urinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress. Biochem Biophys Res Commun 330:731-736 (Pubitemid 40462148)
38. Thomson MJ, Puntmann V, Kaski JC (2007) Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment ? Cardiovasc Drugs Ther 21:195-210 (Pubitemid 46817482)
39. Gloire G, Legrand-Poels S, Piette J (2006) NF-kappa B activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72(11):1493-505 (Nov 30)
40. Delgado Alves J, Ames PR, Donohue S et al (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686-2694 (Pubitemid 36118933)
41. Martinuzzo ME, Forastiero RR, Kordich L, Carreras LO (2001) Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. Br J Haematol 114:845-851 (Pubitemid 32953742)
42. Galle J, Hansen-Hagge T, Wanner C, Seibold S (2006) Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 185:219-226
43. Fong LG, Parthasarathy S, Witztum JL et al (1987) Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 28:1466-1477 (Pubitemid 18025879)
44. Esterbauer H, Jurgens G, Quehenberger O et al (1987) Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 28:495-509 (Pubitemid 17116184)
45. Kobayashi K, Kishi M, Atsumi T et al (2003) Circulating oxidized LDL forms complexes with 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44:716-726 (Pubitemid 37279673)
46. Hasunuma Y, Matsuura E, Makita Z et al (1997) Involvement of b2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107:569-573 (Pubitemid 27102148)
47. Kobayashi K,Matsuura E, Liu Q et al (2001) A specific ligand for b2-19 glycoprotein Imediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42:697-709 (Pubitemid 32507169)
48. Merrill JT, Zhang HW, Shen C et al (1999) Enhancement of protein S anticoagulant function by b2-glycoprotein I, a major target antigen of antiphospholipid antibodies: b2-glycoprotein I interferes with binding of Protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 81:748-757 (Pubitemid 29216562)
49. Balasubramanian K, Maiti SN, Schroit AJ (2005) Recruitment of beta-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis. Apoptosis 10:439-446 (Pubitemid 40603496)
50. Tsimikas S (2006) Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 8:55-61
51. Ames PRJ, Delgado Alves J, Lopez LR et al (2006) Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin Dev Immunol 13:1-9
52. Brown MS, Goldstein JL (1985) Scavenger cell receptor shared. Nature 316:680 -681
53. Yamamoto T, Davis CG, Brown MS et al (1984) The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 39:27-38 (Pubitemid 15218222)
54. Ramprasad MP, Fischer W, Witztum JL et al (1995) The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci USA 92:9580-9584
55. Rigotti A, Acton SL, Krieger M (1995) The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 270:16221-16224
56. Sorenson RC, Bisgaier CL, Aviram M et al (1999) Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19:2214-2225 (Pubitemid 29422255)
57. Khuseyinova N, Koenig W (2006) Apolipoprotein A-I and risk for cardiovascular diseases. Curr Atheroscler Rep 8(5):365-373 (Sep) (Pubitemid 44340180)
58. Batuca JR, Ames PRJ, Amaral M, Favas C, Isenberg DA, Delgado Alves J (2008) Anti-atherogenic and anti-inflammatory properties of high density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (in press)
59. Ritis K, Doumas M, Mastellos D et al (2006) A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 177:4794-4802 (Pubitemid 44469814)
60. Ramos-Casals M, Campoamor MT, Chamorro A et al (2004) Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 13:777-783 (Pubitemid 39457439)
61. Redecha P, Tilley R, Tencati M et al (2007) Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood 110:2423-2431 (Pubitemid 47523163)
62. Ames PRJ, Batuca J, Delgado Alves J et al (2008) Primary antiphospholipid syndrome: a low-grade auto-inflammatory disorder? Rheumatology (in press)
63. Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE (2006) Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther 8:R81
64. Greenwood J, Mason JC (2007) Statins and the vascular endothelial inflammatory response. Trends Immunol 28:88-98 (Pubitemid 46178495)
65. Ames PRJ, Tommasino C, Alves J et al (2000) Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. Lupus 9:688-695 (Pubitemid 32011795)
66. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA (2006) Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33:355-357 (Pubitemid 43209314)
67. Trappe R, Loew A, Thuss-Patience P, Dorken B, Riess H (2006) Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody ritux-imab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 85(2):134-135 (Feb) (Pubitemid 43085311)
68. Ames PR, Tommasino C, Fossati G, Scenna G, Brancaccio V, Ferrara F (2007) Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol 86(3):227-228 (Mar) (Pubitemid 46195998)